Encorafenib

Contraindicated

Encorafenib Doravirine Pifeltro Reduced doravirine exposure, reduced efficacy of doravirine and an increased risk of doravirine resistance Details Encorafenib Atazanavir Reyataz Reduced atazanavir exposure, reduced efficacy of atazanavir, increased encorafenib exposure and an increased risk of QT interval p... Details Encorafenib Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Encorafenib Bepridil An increased risk of QT interval prolongation Details Encorafenib Cisapride Propulsid® Increased risk of QT interval prolongation Details Encorafenib Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Encorafenib Dronedarone Multaq An increased risk of QT interval prolongation, increased encorafenib exposure, an increased risk of encorafenib-related adverse re... Details Encorafenib Ensitrelvir Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects, reduced ensitrelvir exposure... Details Encorafenib Fluconazole Diflucan Increased encorafenib exposure, an increased risk of encorafenib-related adverse events and an increased risk of QT interval prolo... Details Encorafenib Ketoconazole Extina Increased encorafenib exposure, an increased risk of encorafenib-related adverse events and an increased risk of QT interval prolo... Details Encorafenib Lenacapavir Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Encorafenib Levoketoconazole Recorlev An increased risk of QT interval prolongation and torsades pointes, an increased CYP3A4 substrate exposure and an increased risk o... Details Encorafenib Lorlatinib Lorbrena Reduced encorafenib exposure, reduced lorlatinib exposure and an increased risk of serious hepatotoxicity Details Encorafenib Mavacamten Camzyos Reduced mavacamten exposure, reduced efficacy of mavacamten, reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 subs... Details Encorafenib Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Encorafenib Mesoridazine An increased risk of QT interval prolongation Details Encorafenib Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Encorafenib Nifedipine Adalat® Reduced NIFEdipine exposure and reduced efficacy of NIFEdipine Details Encorafenib Pimozide An increased risk of QT interval prolongation Details Encorafenib Piperaquine An increased risk of QT interval prolongation Details Encorafenib Posaconazole Noxafil Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Encorafenib Ranolazine Aspruzyo Increased risk of QT interval prolongation; reduced ranolazine exposure Details Encorafenib Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Encorafenib Saquinavir An increased risk of QT interval prolongation, increased encorafenib exposure and an increased risk of encorafenib-related adverse... Details Encorafenib Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Encorafenib Sparfloxacin An increased risk of QT interval prolongation Details Encorafenib Terfenadine An increased risk of QT interval prolongation Details Encorafenib Thioridazine An increased risk of QT interval prolongation Details Encorafenib Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Encorafenib Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Encorafenib Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details Encorafenib Ziprasidone Geodon An increased risk of QT interval prolongation Details Encorafenib Zoliflodacin Reduced zoliflodacin exposure and reduced efficacy of zoliflodacin Details Encorafenib Ketoconazole Topical Extina® Foam Increased encorafenib exposure, an increased risk of encorafenib-related adverse events and an increased risk of QT interval prolo... Details Encorafenib Lenacapavir Injection Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Encorafenib Lenacapavir Oral Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details

Major

Encorafenib Abametapir Increased exposure of CYP3A4 substrate Details Encorafenib Amitriptyline Elavil Increased risk of QT interval prolongation Details Encorafenib Sertraline Increased risk of QT interval prolongation Details Encorafenib Buprenorphine Belbuca Increased risk of QT interval prolongation Details